Variant Bio, a genomics-driven drug discovery company, today announced a multi-year research collaboration with Novo Nordisk to discover novel targets for the treatment of metabolic disease.
President-elect Donald Trump wants to acquire Greenland. This is not merely one of his japes, as it may have been during his ...
The series A fundraising is the biggest ever for a European biotech firm, according to the data provider PitchBook.
Newly launched company, Verdiva Bio, is aiming to advance oral and injectable drugs for obesity, with it backed by an ...
Comedian Nikki Glaser, host of the 2025 Golden Globe Awards ceremony, dove right in at the start of her opening monologue: ...
Hosted on MSN29d
A next-gen Ozempic falls short in a drug trial — and Novo Nordisk stock plunges 20%The logo of Danish pharmaceutical company Novo Nordisk is pictured at their headquarters in Bagsvaerd outside of Copenhagen, Denmark on February 1, 2017. Novo Nordisk (NVO) released mixed clinical ...
Kepler Capital analyst David Evans maintained a Hold rating on Novo Nordisk (0QIU – Research Report) on January 17 and set a price target of ...
Novo Nordisk (NVO) reported headline results from STEP UP, a phase 3b trial in the global STEP programme. The trial achieved primary ...
Novo and Valo originally partnered in September 2023 in an agreement to develop up to 11 drugs. With the expanded agreement, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback